{"@id":"https://bioecon.ru/technology/macrophage-repolarization-therapy/","@type":"Technology","cluster":"therapeutics-platforms","formats":{"html":"https://cn.bioecon.ru/technology/macrophage-repolarization-therapy/","json":"https://cn.bioecon.ru/api/v1/technology/macrophage-repolarization-therapy/index.json"},"id":"macrophage-repolarization-therapy","industries":["pharma","biomanufacturing"],"lang":"cn","links":{"industries":["https://bioecon.ru/industries/pharma/","https://bioecon.ru/industries/biomanufacturing/"],"suppliers":["https://bioecon.ru/companies/novartis/","https://bioecon.ru/companies/agc-biologics/","https://bioecon.ru/companies/united-therapeutics/","https://bioecon.ru/companies/lonza-group/","https://bioecon.ru/companies/astrazeneca/","https://bioecon.ru/companies/hlb-genex/","https://bioecon.ru/companies/bioviva/","https://bioecon.ru/companies/newlimit/","https://bioecon.ru/companies/minicircle/","https://bioecon.ru/companies/anft-association-of-nature-forest-therapy/","https://bioecon.ru/companies/retro-biosciences/","https://bioecon.ru/companies/biohaven/"]},"maturity":7,"name":"肿瘤相关巨噬细胞M1/M2表型重极化免疫疗法","regions":["ch","eu","us","cn"],"risk":"medium","section":"technology","sector":"health-biomedicine","sources":[{"date":"2026-11-22","entity":"Swiss Biotech Directory 2026","kind":"vendor","urls":["https://www.swissbiotech.org/directory/"]}],"stages":[{"n":1,"title":"巨噬细胞表型极化关键靶点验证"},{"n":2,"title":"高特异性重极化调控分子开发"},{"n":3,"title":"体外肿瘤吞噬与抗原交叉呈递测定"},{"n":4,"title":"实体瘤间质免疫微环境重构"}],"summary":"通过靶向关键表型重塑受体，将肿瘤微环境中的免疫抑制型、促血管新生M2型巨噬细胞逆转重极化为促炎、具备抗原呈递与吞噬活性的M1型效应细胞。","url":"/technology/macrophage-repolarization-therapy/","verified":"2026-11-22"}